Trial Profile
A Randomized, Parallel-group, Open-Label, Pharmacokinetic and Safety Study With Adalimumab in Chinese Subjects With Mild Rheumatoid Arthritis.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Abbott Laboratories
- 23 Jun 2016 Results of safety analysis of this and other trials published in the Annals of the Rheumatic Diseases.
- 15 Apr 2008 New trial record.